Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
MedImmune And Wuxi Team Up In China
by Jean-François Tremblay
September 17, 2012
| A version of this story appeared in
Volume 90, Issue 38
MedImmune, the biologics unit of AstraZeneca, and the Chinese R&D contractor WuXi AppTec have agreed to set up a joint venture to conduct clinical trials on, register, and sell one of MedImmune’s drug candidates in China. The candidate, MEDI5117, aimed at treating autoimmune and inflammatory diseases, is currently in Phase I clinical trials in the U.S. and Europe. The joint venture plans to produce MEDI5117 in China because the country’s regulations require domestic manufacturing of a drug candidate that is not already commercially approved in other countries.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter